<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726868</url>
  </required_header>
  <id_info>
    <org_study_id>CCE-001</org_study_id>
    <nct_id>NCT01726868</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism</brief_title>
  <official_title>Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Community Health Care Organization Sendai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Community Health Care Organization Sendai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate efficacy and safety of blood purification therapy on
      renal dysfunction by cholesterol crystal embolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of chronic hemodialysis</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose of drugs</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of lower limb amputation</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gangrene</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of multi organ failure</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cholesterol Embolism</condition>
  <arm_group>
    <arm_group_label>Liposorber LA-15 System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liposorber LA-15 System</intervention_name>
    <description>Six sessions of blood purification treatment with Liposorber LA-15 System.</description>
    <arm_group_label>Liposorber LA-15 System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet all of the following criteria.

          -  Patients who had cardiac catheterization or vascular surgery in the last 24 weeks
             before the time of obtaining informed consent.

          -  Patients who satisfy all of the following criteria or are diagnosed as CCE by skin or
             renal biopsy.

               1. Patients with progressive renal dysfunction in the course of weeks or months.

               2. Patients with skin lesions such as livedo reticularis of lower extremities or
                  blue toe syndrome.

               3. Eosinophil count is more than 400 per microliter.

          -  Patients who or patients whose legal representative understood the requirements of the
             study and signed the informed consent forms.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded.

          -  Patients with contraindication to anticoagulant (Nafamostat Mesilate).

          -  Blood purification therapy is inapplicable because of severe heart failure, acute
             myocardial infarction, severe arrhythmia, acute stroke, or severe uncontrollable
             hypertension or hypotension.

          -  Patients with body weight less than 40kg.

          -  Patients with a history of allergic reaction or hypersensitivity to blood
             purification.

          -  Patients who cannot stop taking ACE inhibitors.

          -  Patients with any disease in which corticosteroid, statin are contraindicated.

          -  Patients participated in another clinical trial or study at the time of obtaining
             informed consent.

          -  Patients receiving chronic hemodialysis.

          -  Otherwise, patients who are judged by the investigator as being unsuitable for
             inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshinobu Sato, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Japan Community Health Care Organization Sendai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshinobu Sato, MD, PhD</last_name>
    <phone>+81-22-275-3111</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Sendai Shakaihoken Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>981-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshinobu Sato, MD, PhD</last_name>
      <phone>+81-22-275-3111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2012</study_first_submitted>
  <study_first_submitted_qc>November 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Japan Community Health Care Organization Sendai Hospital</investigator_affiliation>
    <investigator_full_name>TOSHINOBU SATO</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Embolism, Cholesterol</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

